

Curriculum Vitae
Jeffrey Alan Toretsky, M.D.
Professor with Tenure
Departments of Oncology and Pediatrics
Georgetown University

April 8, 2016

Personal Information

Business Address:
3970 Reservoir Rd N.W.
Room 311 West
Washington, D.C. 20057-1469
Office number: 202-687-8655
Fax number: 202-687-1434
jat42@georgetown.edu

Home Address:
9510 Clement Rd.
Silver Spring, MD 20910
301-588-4444

Place and Date of Birth:
November 8, 1961, Minneapolis, MN

No fluent foreign languages

Licensure

State of Maryland License Number D42381, initially licensed 9/94; inactive 9/30/11
District of Columbia Medical License MD33730, expires 12/31/16

Certifications

American Board of Pediatrics, General Pediatrics, 1991 - 2005
American Board of Pediatrics, Hematology/Oncology, 1994, renewed 2001, 2009

Education

1984 B.S. with honors Biochemistry University of Wisconsin, Madison, WI
1988 M.D. Medicine University of Minnesota, Minneapolis, MN

Post Graduate Training

Internship:

1988- 1989, Duke University Medical Center, Department of Pediatrics, Durham, NC,
Chairman Samuel Katz.

Residency:

1989- 1991, Medical College of Virginia, Department of Pediatrics, Richmond, VA
Chairman Harold Mauer

Pediatric Oncology Fellowship:

1991 - 1994, National Cancer Institute, Pediatric Branch, Bethesda, MD
Chief Philip Pizzo

Post-Fellowship Training:

1994 - 1995, National Cancer Institute, Clinical Pharmacology Branch, Bethesda, MD,
Supervisor Len Neckers

1995 - 1997, National Cancer Institute, Pediatric Branch, Bethesda, MD,
Supervisor Lee Helman

Professional Experience

1997 – 1999, Special Volunteer, Pediatric Oncology Branch, National Cancer Institute,
NIH, Bethesda, MD 20892

1997 – 2002, Assistant Professor, Department of Pediatrics, University of Maryland,
Baltimore. Baltimore, MD

1997 – 2002, Assistant Professor, Program in Oncology, Greenebaum Cancer Center,
University of Maryland, Baltimore. Baltimore, MD

1997 – 2002, Assistant Professor, Program in Molecular and Cell Biology, University of
Maryland, Baltimore. Baltimore, MD

2001 – 2002, Assistant Professor, Department of Biochemistry and Molecular Biology,
University of Maryland, Baltimore. Baltimore, MD

2002 – 2005, Assistant Professor, Department of Oncology, Lombardi Comprehensive
Cancer Center, Georgetown University, Washington, DC

2002 – 2005, Assistant Professor, Department of Pediatrics, Georgetown University,
Washington, DC

2005 – 2011, Associate Professor with tenure, Department of Oncology, Lombardi
Comprehensive Cancer Center, Georgetown University, Washington, DC

2005 – 2011, Associate Professor with tenure, Department of Pediatrics, Georgetown
University, Washington, DC

2011 – present, Professor with tenure, Department of Oncology, Lombardi
Comprehensive Cancer Center, Georgetown University, Washington, DC

2011 – present, Professor with tenure, Department of Pediatrics, Georgetown
University, Washington, DC

2012 – present, Co-director Children's National Medical Center Multi-disciplinary
Sarcoma Clinic, Washington, DC

Biotechnology/Pharmaceutical Experience

2010 - 2013 Founder, TDP Biotherapeutics, Inc.

This start-up obtained grant funding to license and develop YK-4-279
(USPTO granted to Georgetown University, see patents, below) as a
targeted therapy against EWS-FLI1 of Ewing sarcoma.

2014 - present Founder, Tokalas, Inc. Currently a consultant.

This start-up relicensed YK-4-279 (USPTO granted to Georgetown
University, see patents, below) and successfully completed Series A and
Series B financing in order to complete a chemistry program, toxicology,
pharmacokinetics, and manufacturing. Investigational New Drug
application discussion underway with U.S. FDA and plans to file IND 4th
quarter 2015. Clinical trial sites selected and planning underway for
clinical trial to begin 1st quarter 2016.

Honors and Awards

Outstanding Faculty Entrepreneur in Medical Science, Georgetown Business School,
2012

Georgetown University Medical Center Convocation Honoree for Outstanding Research, 2009
Marquis *Who's Who in America* Biography, 2009
National Academies Keck *Futures Initiatives* Conference, 2009
Georgetown University Medical Center Convocation Honoree, 2008
Burroughs Wellcome Clinical Scientist Award in Translational Research, 2008
Connective Tissue Oncology Society Best Pediatric Oncology Poster, 2007
American Society of Clinical Investigation Member, 2007
International Society of Pediatric Oncology Fasanelli Prize, 1999
American Society of Clinical Oncology Young Investigator Award, 1998
National Institutes of Health Fellows Award for Research Excellence, 1997
American Association of Cancer Research Travel Award, 1997
American Society of Pediatric Hematology/Oncology Young Investigator Award, 1996
Max Seham Community Pediatrics Award, 1988

Professional Societies

Biophysical Society, Intrinsically Disordered Protein section, 2011 - present
American Association for Cancer Research, 1996 – present
American Society of Pediatric Hematology and Oncology, 1997 – present
Connective Tissue Oncology Society, 2007 – present
American Association for the Advancement of Science, 1998 – 2006
American Society of Clinical Oncology, 1998 – 2000; 2012 – present
American Academy of Pediatrics, 1991 – 2003
Endocrine Society, 1998 – 2003
IGF Society, 1999 – 2010

Public Service

Local Service

American Cancer Society Intramural Grant Review Committee, 2000 – present
Dr. Arthur Schwartz Award, reviewer 2001

National Service

Grant Review

American Cancer Society study section: Tumor Biology and Endocrinology full member, January 2003 – 2007
NIH CSR special emphasis panel: National Cooperative Drug Discovery Group for Cancer, member, October 25-27, 2004
NIH CSR study section: Basic Mechanisms of Cancer Therapeutics, ad hoc member, June 2006
NIH CSR study section: Tumor Cell Biology, ad hoc member, June 2007, June 2008
VA Merit Reviewer, Ad Hoc
National Cancer Institute Special Emphasis Panel SPORE in Lymphoma, Brain, Head/Neck and Lung Cancers, and Sarcoma, February 2012
Alex's Lemonade Stand Reviewer, 2008 – present

Editorial Boards and Journal Work

Editorial Board Member, *Journal of Clinical Oncology and Research*, September 2013 - present
Editorial Board Member, *PeerJ*, August 2012 – present
Editorial Board Member, *Sarcoma*, July 2012 – present

Founding Editorial Board Member and Associate Editor, *Frontiers in Pediatric Oncology*, May 2011 – present
Editorial Board Member, *Experimental and Therapeutic Medicine*, January 2010 – present
Editorial Board Member, *Pediatric Blood and Cancer*, 2007 – present
Manuscript Reviewer, *Nature Medicine*; *Journal of Clinical Investigation*, *Journal of Pediatric Hematology and Oncology*; *Cancer*; *Cancer Research*; *Oncogene*; *Pediatric Blood and Cancer*; *Laboratory Investigation*; *Molecular Cancer Research*; *Molecular Cancer Therapeutics*, *American Journal of Pathology*, *Nature*, *Lancet Oncology*

Philanthropy/Organizational

Chairman Medical Advisory Board, Children's Cancer Foundation, January 2015-present
Pediatric Track Chair, American Society of Clinical Oncology Annual Meeting, June 2014
Program Committee, American Society of Clinical Oncology Annual Meeting, June 2012 – 2015
Scientific Advisory Board, Make Some Noise: Cure Kids Cancer Foundation, May 2010 – present
Mentorship Panel, American Society for Clinical Investigation/Association of American Physicians Joint Meeting, April 2009
Chairman of Medical Board, Dani's Foundation, 2007– 2014
Children's Oncology Group, Bone Sarcoma Core Committee, 2005 – 2007
Children's Oncology Group, Bone Sarcoma Disease Committee, 2001 – present
Children's Oncology Group, Member of Protocol Committee for AEWS07B1, 2007
American Society of Pediatric Hematology/Oncology, Program Committee, 2003 – 2007
American Association for Cancer Research Annual Meeting Program Committee, 2006
Children's Oncology Group, Young Investigator Committee, 2001 – 2002
American Society of Pediatric Hematology/Oncology, Membership Committee 1998 – 1999
Medical Advisory Board, Children's Cancer Foundation, Baltimore, MD, 1997 – 2014

International Service

Reviewer for Israel Cancer Research Fund (ICRF) 2012 – present
Reviewer for Associazione Italiana per la Ricerca sul Cancro (Italian Cancer Society) 2011, 2012, 2014, 2015
Reviewer for Association for International Cancer Research, United Kingdom, 2011
Reviewer for Bone Cancer Research Trust, United Kingdom, 2008, 2009, 2010
Ewing's Sarcoma International Symposium, April 9-11, 2008, participant
Reviewer for Swiss National Science Foundation, 2006, 2012
Reviewer for Israeli Science Foundation, 2006, 2009, 2010
Ewing's Sarcoma International Symposium, April 14-16, 2005, co-organizer
Dallas, Texas.
Reviewer for Michael Smith Foundation New Faculty Awards, a British Columbia-based foundation to support new faculty at BC Universities, 2004.
Ewing's Sarcoma International Symposium #2, April 22-24, 2002, participant
Virginia.
Ewing's Sarcoma International Symposium #1, September 25-26, 2000, participant

Virginia.

Invited Lectures

1. Pediatric Grand Rounds, Memorial Sloan Kettering Cancer Center, 1/30/97, A pathway of transformation in Ewing's Family of Tumors via the insulin-like growth factor-I receptor.
2. Pediatric Oncology Branch Seminar, National Cancer Institute, 2/20/98, Ewing's Sarcoma Family of Tumors: Avoiding Apoptosis on the Path Towards Transformation.
3. Maryland Hospital for Children's Outreach, 11/19/98, Easton Memorial Hospital. ITP: What Else Can it Be?
4. Easton Memorial Hospital, 11/20/98, Wild Western: Molecular Biology Advances the Cancer Frontier.
5. Greenebaum Cancer Center Grand Rounds, 3/16/98, Ewing's Sarcoma Family of Tumors: Avoiding Apoptosis on the Trail Towards Transformation.
6. Maryland Hospital for Children's Outreach, 3/17/98, ITP: What Else Can it Be?
7. Mercy Medical Center, 1/8/99, ITP: What Else Can it Be?
8. St. Agnes Hospital Grand Rounds, 2/2000, ITP: What Else Can it Be?
9. Children's Hospital of Philadelphia, 9/12/00, Ewing's Sarcoma: What does the EWS/FLI1 fusion protein do and with whom?
10. Medical College of Virginia, 1/17/01, Wild Western: Molecular Biology Advances the Cancer Frontier.
11. Hershey Medical Center, 2/25/01, Ewing's Sarcoma: A Model to Unravel the Mysteries of Oncogenic Transcription.
12. University of Maryland Department of Biochemistry, 9/10/01 EWS/FLI1: A model of Ewing's sarcoma.
13. Lombardy Cancer Center, 9/24/01, EWS/FLI1: A Key to Ewing's Sarcoma.
14. Centre de Recherche de L'Hopital Sainte-Justine, Montreal, Quebec, 11/13/01, EWS/FLI1: A key to diagnosing and treating Ewing's Sarcoma.
15. AFLAC Cancer Center Visiting Professor, Emory University, Atlanta, GA, 12/3/01, EWS/FLI1: A key transcription factor in Ewing's Sarcoma with therapeutic implications.
16. Georgetown University Department of Pediatrics Grand Rounds, 6/6/03, How are we hitting the cancer target?
17. Children's Hospital Los Angeles, Grand Rounds, 4/28/04, Evoking and exploiting EWS/FLI1 in the therapy of Ewing's Sarcoma.
18. Pediatric Academic Societies, 5/1/04, Pediatric Malignancies Provide Unique Cancer Therapy Targets.
19. 18th Annual Pediatric Surgery Symposium at Uniformed Services University of the Health Sciences, 6/10/04, Molecular Targets in Childhood Cancer: Seek and Destroy.
20. Department of Pediatrics, University of Utah, 3/4/05, Molecular Targets and Ewing's Sarcoma.
21. Ewing's Sarcoma 3rd International Nearburg Symposium, University of Texas Southwestern Medical Center, Dallas, TX, 4/14 – 4/16/05
22. Pediatric Academic Societies and American Society of Pediatric Hematology/Oncology, 5/14/05, EWS/FLI1: The Perfect Target?
23. Pediatric Grand Rounds, M.D. Anderson Cancer Center, University of Texas, Houston, TX, 6/20/05, Ewing's Sarcoma: Can Molecular Therapy Hit a Perfect Target?
24. Cancer Research Institute, University of Texas, San Antonio, TX, 11/1/05, Ewing's Sarcoma: Can Molecular Therapy Hit a Perfect Target?

25. Pediatric Grand Rounds, Georgetown University School of Medicine, Washington, D.C., 5/19/06, New Drugs for Childhood Cancer: How to Throw a Rock Through the Glass Ceiling.
26. FASEB Phosphatase Meeting, Snowmass, CO, 7/15/06, PTPL1: Is this Phosphatase a Molecular Target for Ewing's Sarcoma?
27. Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, 10/24/06, New Drugs for Childhood Cancer: Exploiting Novel Molecular Targets.
28. Child and Family Research Institute, University of British Columbia, Vancouver, BC, 1/11/07, New Drugs for Childhood Cancer: Exploiting Novel Molecular Targets.
29. Sarcoma Mini-Symposium Visiting Lectureship, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 2/14/07, New Drugs for Childhood Cancer: Exploiting Novel Molecular Targets.
30. National Cancer Institute, Pediatric Oncology Branch Rounds, 2/21/08, New Drugs for Childhood Cancer: Exploiting Novel Molecular Targets.
31. Broad Institute, MIT, Cambridge, MA, 3/25/08, New Drugs for Childhood Cancer: Exploiting Novel Molecular Targets.
32. Glaxo-Smith-Kline, Seminar, Collegeville, PA, 3/31/08, New Drugs for Childhood Cancer: Exploiting Novel Molecular Targets.
33. Rett Nearburg International Ewing's Sarcoma Symposium IV, Dartmouth College, Hanover, NH, 4/10/08, EWS-FLI1: Progression from Oncogene to Partner to Poison.
34. PROTHETS, European Ewing's Sarcoma Project, Rome, Italy, 6/6/08, EWS-FLI1: Progression from Oncogene to Partner to Poison.
35. Children's Hospital of Philadelphia, Center for Childhood Cancer Research Seminar Series, 9/16/08, New Drugs for Childhood Cancer: Exploiting Novel Molecular Targets.
36. Targeted Therapy for Childhood Cancers, Georgetown University Lombardi Cancer Center, April 15, 2009, Targeted Therapeutics for Ewing's sarcoma.
37. Distinguished Scientists Seminar Program, Department of Biochemistry and Molecular Biology, University of South Alabama, Mobile, AL, 4/30/09, EWS-FLI1 to PTPL1: Why does an oncogene make a phosphatase?
38. Pediatric Cancer Data Portal Workshop, Georgetown University Lombardi Cancer Center, Washington, DC, 5/18/09. Targeted therapies for pediatric cancers – Ewing's Sarcoma.
39. Children's Oncology Group Meeting, Dallas, TX, 9/29/09, Modulation of IGF Signaling in Ewing's Sarcoma.
40. University of Minnesota Masonic Cancer Center, Minneapolis, MN, 12/4/09 Small molecule targeting of the disordered oncoprotein EWS-FLI1 in Ewing's Sarcoma.
41. Children's National Medical Center Research Seminar, Washington, DC, 1/5/10, Disordered proteins provide amazing small molecule therapeutic targets.
42. Children's National Medical Center Pediatric Grand Rounds, Washington, DC, 1/6/10 Therapeutic targeting of the oncoprotein EWS-FLI1: the Achilles' Heel of Ewing's Sarcoma.
43. Vanderbilt-Ingram Cancer Center, Nashville, TN, 1/7/10, EWS-FLI1 is a therapeutic target and a disordered protein.
44. Johns Hopkins Translational Medicine Series, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 1/20/10, Small molecule targeting of EWS-FLI1 to modulate transcription and create new therapies for Ewing's Sarcoma.
45. Children's Hospital of Los Angeles, Los Angeles, CA, 3/10/10, Small molecule targeting of EWS-FLI1 to modulate transcription and create new therapies for Ewing's Sarcoma.

46. Sarcoma Foundation of America's Annual Patient Educational Conference, New York, NY, 4/25/10, Advances in Treatment and Research in Ewing's Sarcoma: Seven Easy Steps to Make a Targeted Anti-Cancer Drug.
47. American Association for Cancer Research 101st Annual Meeting, Washington, DC, 4/20/10, Therapeutic Targeting of EWS-FLI1: Small Molecule Protein-Protein Interaction Inhibitors.
48. American Society for Clinical Oncology, Chicago, IL, 6/7/10, *Discussion Leader*: Targeting the IGF-IR pathway: Curiosity or Cure?
49. American Society for Clinical Oncology, Chicago, IL, 6/7/10, *Educational Lecture*: Can Molecular Targets Translate to Therapeutics? Novel therapeutic opportunities for sarcomas based upon disordered chromosomal translocation fusion proteins.
50. A.I. Dupont, Wilmington, DE, October 11, 2010, Disorderly Conduct Can Cause Cancer and Lead to Novel EWS-FLI1 Targeted Therapy.
51. St. Anna's Kinderspital, Vienna, Austria, November 9, 2010, From Disorderly Conduct to Small Molecule Targeting EWS-FLI1 Remains the Villain.
52. Translational Research Interest Group Seminar Series, National Institutes of Health, Bethesda, MD, February 22, 2011, YK-4-279 is a novel small molecule directly targeting EWS-FLI1.
53. Georgia Institute of Technology, Atlanta, GA. March 14, 2011, Of biochemists, synthetic chemists, and molecular biologists: collaboration to discover new drugs for transcription factor cancer targets.
54. Georgetown University Lombardi Comprehensive Cancer Center, March 30, 2011, Washington, DC, Drugs and Thugs: Destroying Disordered Proteins.
55. Pharmacology Department, Georgetown University, Washington, DC, May 6, 2011.
56. Memorial Sloan-Kettering Cancer Center, New York, NY, May 19, 2011, Directly Targeting the Ewing Tumor Stem Cell via EWS-FLI1.
57. Washington Hospital Center, June 10, 2011, Washington, DC, Achieving the Ultimate Therapeutic Index: Targeting Tumor-Specific Fusion Proteins.
58. Maria Sklodowska-Curie Memorial Institute of Oncology, Krakow, Poland, July 4, 2011, Developing therapies that target oncogenic fusion proteins derived from chromosomal translocations.
59. Molecular Therapeutics of Cancer Conference, Pacific Grove, CA, July 10-13, 2011, Drugging the Undruggable, Thinking the Unthinkable.
60. Columbia University Medical Center, New York, NY, July 27, 2011, Small molecules and intrinsically disordered proteins: Perhaps the next generation of anticancer therapy.
61. Frontiers in Oncology Lectureship, University of Maryland Greenebaum Cancer Center, Baltimore, MD, September 21, 2011, Disordered Proteins Cause Challenges, but Open Opportunities when Targeting Tumorigenic Transcription.
62. 4th Semi-Annual Musculoskeletal Tumor Symposium, Cincinnati, OH, October 17, 2011. New targeted inhibitors for Ewing sarcoma.
63. European Commission-Funded Network on Cancer Research in Children and Adolescents (ENCCA) Ewing's Sarcoma Biology Subnetwork meeting Vienna, Austria, December 20, 2011.
64. Children's National Medical Center, Washington, DC, January 30, 2012, Drugging the Undruggable: PK Models and Nuclear Complexes.
65. University of Virginia, Charlottesville, VA. February 2, 2012, A small molecule that disrupts RNA Helicase A from the oncogenic transcription factor EWS-FLI1 reduces tumor growth.

66. Texas Children's Hospital, Baylor College of Medicine, Houston, TX, March 29, 2012, Drugging the Undruggable: PK Models Useful to Destroy Nuclear Complexes.
67. AACR Annual Meeting, Chicago, IL, March 31, 2012, Meet-the-Expert Session, Undruggable Therapeutic Targets and How to Target Them.
68. Transcription and Cancer Meeting, Banbury Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, April 9-12, 2012, Small-molecule targeting of fusion protein transcription factors and the biochemistry of intrinsically disordered proteins.
69. Society for Paediatric Oncology and Haematology (Gesellschaft für Pädiatrische Onkologie und Hämatologie - GPOH) Meeting, Berlin, Germany, May 9-13, 2012, Keynote Address.
70. National Institutes of Health, Frederick, MD, July 20, 2012, Intrinsically Disordered Proteins Make Great Drug Targets.
71. Pediatric Grand Rounds, Georgetown University Hospital, Washington, DC, September 7, 2012, Novel treatment for Ewing sarcoma is on the way from idea to clinical trial.
72. European Science Foundation-European Molecular Biology Organization Conference on Molecular Biology and Innovative Therapies in Sarcomas of Childhood and Adolescence, Polonia Castle, Pultusk, Poland, September 29 - October 4, 2012, Targeting fusion protein transcription factors based upon their intrinsic disorder.
73. Cornell University, Ithaca, NY, October 8, 2012, Small-molecule targeting of fusion protein transcription factors and the biochemistry of intrinsically disordered proteins.
74. Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, October 23, 2012, Drugging the Undruggable: Targeting Transcription in Ewing Sarcoma.
75. Chemotherapy Foundation Symposium XXX, New York, NY, November 6-10, 2012, Novel approaches to the treatment of Ewing sarcoma.
76. The University of Maryland School of Medicine, Baltimore, MD, January 18, 2013
77. The University of Kansas, Lawrence, KS, January 28, 2013.
78. Cook Children's Hematology-Oncology Grand Rounds, Forth Worth, TX, February 8, 2013.
79. 8th International Conference on Pediatric Renal Tumor Biology, Bethesda, MD, May 9th, 2013, Keynote Address. Targeting fusion protein transcription factors based upon their intrinsic disorder.
80. University of Colorado Cancer Center, Denver, CO, May 10th, 2013, Keynote Address.
81. Children's Oncology Group Sarcoma Biology Session, October 9th, 2013.
82. Rett Nearburg International Ewing's Sarcoma Symposium V, San Diego, CA, November 7, 2013, EWS-FLI1: Balance and Regulation to Achieve Oncogenesis.
83. Georgetown University Sarah Stewart Lectureship, Feb 6, 2014. Designing a Drug for the Ideal, but "Undruggable", Cancer Target.
84. Targeted Anti-Cancer Therapy Conference, March 2014. Drugging the Undruggable: Small Molecule Protein - Protein Interaction Inhibitors
85. Instituto Ortopedico Rizzoli, Bologna, Italy. April 1, 2014. Novel Partner Proteins and Functions for EWS-FLI1.
86. American Society of Clinical Oncology, Chicago, IL. May, 2014. Pediatric Oncology Highlights of the Day.
87. American Society of Clinical Oncology, Chicago, IL. May, 2014. Targeted Therapy in Pediatric Cancer: Where are we now and where do we go from here?
88. Medical College of Virginia/Virginia Commonwealth University, Pediatrics Grand Rounds, Richmond, VA., May 6, 2014. Targeting EWS-FLI1: The Achilles' 'HEAL' of Ewing Sarcoma.
89. CureSearch Annual Symposia, Washington, DC. Sept 2014. Targeting the

- 'Undruggable' EWS-FLI1: Achilles' 'HEAL' of Ewing Sarcoma.
90. Ohio State University, Columbus, OH, Nov 2014. Small Molecule Targeting of EWS-FLI1: Killing Cancer While Gaining Mechanistic Insights.
 91. Texas Children's Hospital, Houston, TX April 2015. EWS-FLI1 regulates alternative splicing: what is the role of splicing in Ewing sarcoma oncogenesis?
 92. American Society of Clinical Oncology, Chicago, IL. June, 2015. Poster session discussant on basic research towards translation.
 93. ENCCA Ewing sarcoma meeting, Institute Curie, Paris, France, June 2015. Challenges to Successfully Targeting EWS-FLI1.
 94. St. Jude Children's Hospital, Memphis, TN, November 2015. Small Molecule Targeting of EWS-FLI1: Killing Cancer While Gaining Mechanistic Insights.
 95. University of Muenster, Departments of Medicine and Pediatric Oncology, Muenster, Germany, April 2016. Creating a Drug for the Ideal, but "Undruggable", Cancer Target.
 96. EuroEwing Strategy Meeting, Muenster, Germany, April 2016. Creating a Drug for the Ideal, but "Undruggable", Cancer Target.
 97. University of Copenhagen, Novo Nordisk Center for Protein Research, Copenhagen, Denmark, April 2016. Small Molecule Perturbation of EWS-FLI1 Networks: Killing Cancer While Gaining Mechanistic Insights.
 98. Exiqon Life Sciences, Vedbaek, Denmark, April 2016. Small Molecule Perturbation of EWS-FLI1 Networks: Killing Cancer While Gaining Mechanistic Insights.
 99. American Association for Cancer Research, Pediatric Cancer Working Group Special Scientific Session, New Orleans, LA, April 2016. Creating a Drug for the Ideal, but "Undruggable", Cancer Target.
 100. Gordon Research Conference, Intrinsically Disordered Proteins, Les Diablerets, Switzerland, June 2016.

Georgetown University Service

Program Leader, Molecular Oncology Program (MOP), 2011 to present
 Biacore Core Oversight Committee, 2004 to present
 Tumor Biology Oversight Committee, 2003 to present
 Macromolecular Analysis Core Oversight Committee, 2004 to present
 Targeted Therapy for Childhood Cancers, co-chaired/organized symposium that brought speakers from around country to Georgetown, April 15, 2009
 Clinical Faculty Task Force, August 24, 2008
 Georgetown University Medical Center Organizational Design Team, 2008 – 2009
 Humanomics Symposium Committee Chairman, 2007 – 2008
 Georgetown University Medical Center Research Committee, 2005 – 2008
 Georgetown University Medical Center Junior Faculty Mentor, 2008
 Georgetown University Medical Center Organizational Design Team, 2008
 School of Medicine Committee on Medical Education, 2004 – 2005
 Drug Discovery Taskforce, 2002 – 2005
 Transgenic Animal Imaging Taskforce, 2003 – 2005
 Proteomics Task Force, 2004 to 2005

University of Maryland Service

Department of Pediatrics Research Advisory Committee, 1999 – 2002
 Program in Molecular and Cellular Biology, Seminar committee, 2001 – 2002
 Program in Molecular and Cellular Biology, MD/PhD committee, 2000 – 2002
 Program in Oncology, Experimental Therapeutics committee, 1999 – 2002

Program in Oncology, Drug Discovery Working Group, 2001 – 2002
Dean's Research Advisory Committee, Chairman Howard Dickler, 2000
Dean's Task Force on Mentoring, Chairman James Nataro, 1999

Teaching Activities

Georgetown University

Pharmacology Elective in Oncology 2012- present
Small group leader, Medical Student Evidence Based Medicine 2006 to 2012
Course Co-Director, Current Topics in Tumor Biology, 2003 to 2010
Lecturer, Medical Student Year 2 Pathophysiology (hematology and oncology)
Lecturer, Tumor Biology 508, 2003 to present
Small group leader, Medical Student Year 2 Pathophysiology, 2003
Bedside teaching with residents and medical students 4 hours/week and 4 weeks per year of inpatient attending teaching, 2002 – 2010

Faculty Development Mentor

Aykut Üren, MD, 2002 – present (Dean's Award for Career Development; Golden Apple Award for Excellence in Teaching, 2010). Now full Professor.
Joanna Kitlinska, PhD., 2002 – present (Dean's Award for Career Development), Promoted to Associate Professor, with Tenure 2015
Brian Rood, MD, NIH K08, 2006 - 2011, Assistant Professor George Washington University and Attending Children's National Medical Center
Scott Borinstein, MD., 2009 - 2013., Promoted to Associate Professor.
Rebecca Riggins, PhD., 2013 - present
Chunling Yi, PhD., 2011 – present

Post-Doctoral Fellows

Aykut Uren, MD 1999-2002, tenured Professor Georgetown
Silke Schlottman, PhD, 2006 – 2011; Program Officer at FDA
Nilay Shaw, MD, 2011-2013, Tenure-track position at Ohio State University
Emily Soni, MD, 2010-2013, Tenure Track position at University of Rochester
Hayriye Verda Erkizan, PhD, 2004 – 2015, Research Scientist at VA hospital
Stefan Zoellner, MD, 2013-2016, Faculty University of Muenster, Muenster, Germany
Yasmine Saygideger, MD., PhD awarded 2015. Faculty, Ismir, Turkey.
Suthee Rapisuwon, MD., 2013- 2015. Research Assistant Professor, GU
Saravana Selvanathan, PhD, 2010 - present

Graduate Students

Julie Barber-Rotenberg, PhD 2012; post-doctoral fellowship Wistar Institute, Marmorstein Lab
Elspeth Beauchamp, Thesis Committee, PhD 2010; Assistant Professor, Northwestern University
Ogan Abaan, PhD 2008; post-doctoral fellowship NIH, NCI
Jordan Li, PhD Thesis Committee; PhD 2012
Magdalena Czarnecka, Thesis Committee; PhD 2012
Jean-Baptiste Mazzarti, Thesis Committee; PhD 2012
David Kodack, Thesis Committee, PhD 2009
Jaime Guidry, Thesis Committee Chair, PhD 2009

Kevin Johnson, Thesis Committee, PhD 2008
Erin Mulbrandt, Thesis Committee, PhD 2008
Tyler Lahusen, Thesis Committee, PhD 2007
Cari Lee, Thesis Committee, PhD 2004, Advisor Todd Waldman
Annabell Oh, Thesis Committee, PhD 2006, Advisor Anton Wellstein
Silvina Frech, Comprehensive Exam 2004
Erin Mulbrandt, Comprehensive Exam 2004
Dora Stylianou, Comprehensive Exam 2003
Margaret Emblom, . Comprehensive Exam 2003
Gregory Maddox, MS 2005
Kelsy McCarty, MS 2004
Dori Paccitil, MS 2003

Rotating Graduate Students

Deanna Tiek, PhD student 2014
Will Kietzman, PhD student 2013
Darius Gaymon, MS student, 2012-2013
Anand Lakhkar, PhD student, 2012
Alana Lelo, MD/PhD student, 2012
Nguyen Nguyen, PhD student, 2011
Tara Gelb, PhD Student, 2011
Rupa Lalchandani, PhD student, 2010
Sonya Parpart, PhD student, 2009
Lymor Ringer, PhD student, 2007

Undergraduate Project Mentees

Sarah Pickard, Georgetown University Howard Hughes Scholar 2004-6
Stanford Medical School 2006 - 2010
Pediatric Residency at Harvard/Boston Children's Hospital 2010 - 2013
Nilan Schnure, Montgomery Blair Science-Math Magnet Student 2007;
Princeton University Undergraduate 2009 – 2012
University of Pennsylvania Medical School 2013-
Alison O'Neill, Georgetown University Undergraduate 2008 – 2011
Georgetown Medical School 2012 - present

GU Department of Pediatrics Mentees

Haifa Mtaweh, MD, Completed Pediatric Residency 2010
To begin Pediatric Cardiology at U Toronto/Toronto Sick Children's

Post-baccalaureate Trainees, POST-laboratory accomplishments:

Sarah Zaidi, Residency in Pediatrics, Texas Children's Hospital, currently
pediatric pulmonary attending Children's National Medical Center
Naamah Zitomersky, University of Maryland Medical School 2004, Pediatric
Residency, Fellowship in Pediatric Gastroenterology, Attending
physician Boston Children's Hospital
Amy Skversky, UMDNJ New Jersey Medical School 2005, Pediatric
Residency, Fellowship Pediatric Nephrology, Ped Nephrologist
Yu-Feng Sun, University of Maryland Medical School 2007, Psychiatry
Residency, practicing psychiatrist

Amy Levinson, Drexel University Medical School 2008, Pediatric Residency Fellowship in Pediatric Endocrinology at Boston Children's Hospital
Kevin Chen, Georgetown University Medical School 2009, Med-Peds Resident USC
Lauren Scher (Jacobwitz), Georgetown University Medical School 2010, Anesthesiology residency Johns Hopkins
Alison O'Neill, Georgetown University Medical School 2012
Sarah Ellen Gamble, Georgetown University Medical School 2012
Ryan Commins, Georgetown University Medical School 2012
Faezeh Razjouyan, Howard University Medical School 2012
Garrett Graham, 2012 –
Jeffrey Schneider, 2012 – 2014, MSTP NYU 2014 -

Summer Intern Mentees

Samantha Halpin, Endocrine Society Fellowship 2003
Brandon Baird, 2003 CURE program
Alex Mazerov, Montgomery Blair Science-Math Magnet Student 2005
Audrey Kubetin, Montgomery Blair Science-Math Magnet Student 2006
Samuel Prager, Montgomery Blair Science-Math Magnet Student 2006
Amber Makani, Georgetown University Howard Hughes Scholar 2007
Charles Kong, Montgomery Blair Science-Math Magnet Student 2008
Eyerusalem Befkadu, University of Maryland-Baltimore County Undergraduate 2009, PharmD to be completed...
Aaron Plave, Bethesda-Chevy Chase High School Summer 2011
Nadia Turner, Albert Einstein High School Summer 2012, 2013
Sarah Jaffee, University of Rochester, 2013, 2014
Vivian Wang, Poolesville High School Student 2012
Arielle Hollies, Mont County High School, 2013, 2014
Talia Migdal, Washington University 2013, 2014
Alex Hemmer, Albert Einstein High School 2013
Sam Swire, Williams College 2014
Sydney Parks, Thomas Jefferson High School 2015
Jeffrey Blackman, Washinton University 2015

University of Maryland

University of Maryland Pathology 760, 30 students, lecturer 1998 - 2002
Clinic preceptor for Pediatric Hematology/Oncology for year 1 residents, 4 hours/week 1998-2001
Bedside teaching with residents and medical students 4 hours/week, 1997 - present
Medical School Second Year Hematology Lab Instructor, 1998

Graduate Student Committees

Tracy Lessor, PhD awarded 1999
Kara Smolinski, PhD awarded 2000
Dehe Kong, PhD awarded 2000 (thesis reader)
Carrienne Judge, MS awarded 2001

Summer Intern Mentees

Cadence Berrian 2001

Continuing Medical Education Instruction

Pharmaceutical Education and Research Institute (PERI), Arlington, VA
Cancer: Pathophysiology, Current Therapies, Clinical Trials, and Drug Development, 2003, 2005 - 2010
Cancer 101: A Basic Overview of Current Therapies for New Oncology Researchers, 2006 – 2009

Scholarship and Research

ACTIVE Research Grants

St. Baldrick's Foundation (Toretsky - PI) 07/01/14 – 06/30/16 (NCE)

This proposal will establish the full transcriptome of Ewing sarcoma as well as all expressed alternatively spliced variants. It will directly compare single molecule real time sequencing (SMRT) using a PacBio instrument to 100 million paired reads from an Illumina instrument. This proposal will also explore using isoform-specific RNA hybridization in tumors as a diagnostic and pharmacodynamic biomarker.

Hyuandai Foundation (Toretsky - PI) 07/01/15 - 06/30/17

This proposal supports analyzing the role of YK-4-279 upon metastatic models of ES alone and in combinatorial therapy.

Allen B. Slifka Foundation (Toretsky - PI) 07/01/15 - 06/30/17

This proposal supports developing pharmacodynamic markers of YK-4-279 and analogs for clinical development.

5 P30 CA051008-16 (Lou Weiner) 09/30/1990 – 04/30/2019

NIH *Cancer Center Support Grant: This grant provides core support for the cancer center. Toretsky role is Program Leader of Molecular Oncology Program.*

COMPLETED RESEARCH SUPPORT

R01 CA138212-01 (Toretsky) 09/01/2008 – 08/31/2015 (NCE)
NIH/NCI \$2,543,385

“Isolation and small molecule targeting of Ewing’s Sarcoma stem cells”
The proposal will identify Ewing’s Sarcoma stem cells and determine the key signaling pathways used by these cells. In addition, the genetic profiles of the stem cells will be developed. Small molecules will be used to target the stem cells to determine if they are differentially sensitive compared to total populations of tumor cells.

R01CA133662-01A2 (Toretsky) 12/01/2008 – 11/30/2014 (NCE)
NIH/NCI Score 0.8%. \$1,535,000

“Novel Compounds to Inactivate Oncogenic Fusion Proteins”
RNA helicase cooperation with an oncogenic transcription factor is novel, thus we propose the following hypotheses to interrogate and expand our discovery. We hypothesize that the interaction of RHA with EWS-FLI1 results in a potent transcriptional activator/coactivator complex amplifying the functions of both proteins and together drive the malignant phenotype of ESFT.

1007487 (Toretsky) 07/01/2008 – 06/30/2015
Burroughs-Wellcome Foundation \$750,000

“Novel cancer therapeutics based upon oncogenic fusion-protein transcription factors”

This project will evaluate small molecules that disrupt RHA from EWS-FLI1 as potential therapeutics patients with Ewing’s Sarcoma Family of Tumors.

RC4 RFA-OD-10-005 (Toretsky) 09/30/2010 – 08/31/2014
NIH/NCI Score: 1% \$4,373,380

“YK-4-279 specifically targets ETS family fusion-protein cancers in clinical trial”

The overall ambition of this proposal is to optimize delivery methods and obtain toxicologic data for submission of an investigational new drug (IND) application leading to a first-in-class, first-in-human clinical trial. The experiments presented in this proposal will potentially stimulate the opening of a novel area of pharmacologic development, that of small molecule protein-protein interaction inhibitors (SMPPII) for transcription.

*Creation of a PDGF-C Autocrine Loop by HIC1 Inactivation, Principal Investigator, Brian R. Rood, **Mentor Jeffrey Toretsky, no support**, NIH K08NS051477, 12/01/2006 – 11/30/2011*

*Signaling Pathways that Determine Ewing’s Sarcoma Outcome, **Principal Investigator Jeffrey Toretsky**, NIH/NCI R01 CA88004, 02/01/2000 – 05/31/09. Total Costs \$1,163,632.*

*Akt Inhibitors to Treat Ewing’s Sarcoma, **Principal Investigator Jeffrey Toretsky**, 20% effort. NIH R41 CA102841-01A1, 2 years, total direct costs \$540,592, 08/02/2004 – 08/01/2006.*

*Shared Instrument Grant for a Biacore T100, **Principal Investigator Jeffrey Toretsky**. NIH S10 RR022388-01. Total and direct costs \$320,000. Awarded 02/28/2006.*

*Targeted regulation of acetylation as novel therapy for Ewing’s sarcoma, **Principal Investigator Jeffrey Toretsky**, Alex’s Lemonade Stand Foundation, 07/01/2009 – 06/30/2011, \$200,000.*

*IGFIR in Human GI Tumors, **Co-investigator Jeffrey Toretsky**, NIH R01 CA78843-01, Total Direct Costs, \$834,899. 07/01/1998 - 06/30/2001.*

*Chemotherapy Resistance in Childhood Malignancy, **Principal Investigator Jeffrey Toretsky**, Bear Necessities, \$15,000, 7/01/1999 - 07/01/2000.*

*Bressler Intramural, **Principal Investigator Jeffrey Toretsky**, \$15,000, 07/01/1999 - 07/01/2000*

*American Cancer Society Intramural Research Grant, **Principal Investigator Jeffrey Toretsky**, \$15,000, 07/01/1998 - 07/01/1999*

Young Investigator Award, American Society of Clinical Oncology,
Principal Investigator Jeffrey Toretsky, \$32,500, 07/01/1998 - 07/01/1999

Outcome Markers for Adolescents with Ewing's Sarcoma, **Principal Investigator Jeffrey Toretsky**. Children's Oncology Group Adolescent and Young Adult Committee, 01/01/2007-12/31/2009, direct costs \$30,000.

Ewing's Sarcoma Fusion Protein Interactions, **Principal Investigator Jeffrey Toretsky** Children's Cancer Foundation, 12th year, 12/01/2008 – 11/30/2009, \$123,000

Neuropeptide Y in neuroblastoma: growth, angiogenesis and future therapeutics, PI Joanna Kitlinska, **Co-investigator Jeffrey Toretsky**, 07/01/2006 – 05/31/2011

No Funding Agency Number 11/01/2010 -10/31/2013
Children's Cancer Foundation \$75,000
"Revealing the mechanism of YK-4-279's effect on ESFT cells"
Mentor, Jeffrey Toretsky, no salary support. *Grant provides salary to Research Fellow Hayriye Verda Erkizan, PhD.*

Patents-Awarded

Methods and compositions for treating Ewings sarcoma family of tumors

Patent number: 9290449

Abstract: Compounds, compositions and methods relating to EWS-FLI1 protein inhibitors are provided. The compounds have utility in the treatment of cancers including the Ewing's sarcoma family of tumors.

Type: Grant

Filed: April 11, 2013

Date of Patent: March 22, 2016

Targeting of EWS-FLI1 as anti-tumor therapy

Patent number: 9045415

Abstract: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.

Type: Grant

Filed: March 9, 2010

Date of Patent: June 2, 2015

Targeting of EWS-FLI1 as anti-tumor therapy

Patent number: 8232310

Abstract: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.

Type: Grant

Filed: June 29, 2009

Date of Patent: July 31, 2012

Patents - Filed/pending

Novel F-18 Labeled Annexin V, Synthesis Thereof, and Use. U.S. Patent Application 60/437,719

Peer-Reviewed Publications

1. **Toretsky, JA**, Shahidi, NT, Finlay, JL. Effects of Recombinant Human Interferon Gamma on Hematopoietic Progenitor Cell Growth. Exp. Hematol. 14:182-186 (1986).
2. Rosolen, A., **Toretsky, JA**, Neckers, LM. Antisense inhibition of CHP-100 *c-myc* expression results in reduced *in vitro* growth kinetics and loss of *in vivo* tumorigenesis. Prog. Clin. Biol. Res. 385: 95 - 101 (1994).
3. Rosolen, A., Franscella, E., **Toretsky, JA**, Neckers, LM. Episome generated *c-myc* antisense RNA inhibits growth and tumorigenicity of a human neuroendocrine tumor cell line. Int. J. of Oncology. 6: 175 - 179 (1995).
4. **Toretsky, JA**, Neckers, L, Wexler, LH. Detection of the t(11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors. JNCI 87(5): 385-86 (1995).
5. Blagosklonny MV, **Toretsky J**, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene Sep 7;11(5):933-9 (1995).
6. *Blagosklonny MV, ***Toretsky J**, Bohlen S, Neckers L. Mutant conformation of p53 translated *in vitro* or *in vivo* requires functional HSP90. Proceedings of National Academy of Sciences. 93(16): 8379-83 (1996). (***These authors contributed equally to this project**).
7. **Toretsky, JA**, Connell, Y, Neckers, L, Bhat, NK. Inhibition of EWS-FLI-1 Fusion Protein with Antisense Oligodeoxynucleotides. Journal of Neuro-Oncology, 31: 9-16 (1997).
8. Schulte, TW, **Toretsky, JA**, Ress, E, Helman, L, Neckers, LN. Pax-3 in Ewing's Family of Tumors. Biochemical and Molecular Medicine, 60(2): 121-6 (1997).
9. **Toretsky, JA**, Kalebic, T, Blakesley, V, LeRoith, D and Helman, LJ. The Insulin Like Growth Factor-I Receptor is Required for EWS/FLI-1 Transformation of Fibroblasts. Journal of Biological Chemistry, 272(49): 30822-27 (1997).
10. Choo-Kang, LR, Jones, DM, Fehr, JJ, Eskenazi, AE, **Toretsky, JA**. Cerebral Edema and priapism in an adolescent with acute lymphoblastic leukemia. Pediatric Emergency Care, 15: 110-2 (1999)
11. Souza, RF, Wang, S, Thakar M, Smolinski, K, Yin, j, Tong-Tong, Z, Kong, D, Abraham, J, **Toretsky, JA**, Meltzer, S. Expression of the wild-type insulin-like growth factor-II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene, 18: 4063-68 (1999)
12. **Toretsky, JA**, Thakar, M, Gutkind, S, Eskenzai, A, Frantz, C. Phosphoinositide 3-OH kinase blockade enhances apoptosis in Ewing's Sarcoma Family of Tumors. Cancer Research, 59: 5745-50 (1999)
13. Young, G, **Toretsky, JA**, Campbell, A, and Eskenazi, AE. Recognition of Common Childhood Malignancies. American Journal of Family Practice, 61(7):2144-54. (2000)
14. **Toretsky, JA**, Zitomersky, N, Eskenazi, A, Voigt, RW, Strauch, ED, Sun, CC, Huber, R, Meltzer, SJ, and Schlessinger, D. Glypican-3 expression in Wilms tumor and hepatoblastomas. Journal of Pediatric Hematology and Oncology 23(8): 496-99 (2001).

15. Merino ME, Navid F, Christensen BL, **Toretsky JA**, Helman LJ, Cheung NV and Mackall CL. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation using real-time PCR. Journal of Clinical Oncology, 19:3649-59 (2001)
16. **Toretsky, JA**, Steinberg, SM, Thakar, M, Zitomersky, N, Counts, DR, Pironis, B, Parente, C, Eskenazi, AE, Helman, LJ, Wexler, LH. Insulin-Like Growth Factor Type 1 (IGF-1) and IGF Binding Protein-3 in Patients with Ewing Sarcoma Family of Tumors. Cancer, 92(11):2941-7 (2001).
17. Waldrop C, Kathuria, SS., **Toretsky J**, and Sun C. Myoepithelioma metastatic to the orbit. American Journal of Ophthalmology, 132(4): 594-6 (2001)
18. Mullins M, **Toretsky J**, and Rappoport A. PBK/TOPK Is a Novel Mitotic Kinase Which is Upregulated in Burkitt's Lymphoma and Other Highly Proliferative Malignant Cells. Blood Cells, Molecules and Diseases 27(5):825-829, (2001).
19. **Toretsky, J. A.**, Jenson, J., Sun, C. C., Eskenazi, A. E., Campbell, A., Hunger, S. P., Caires, A., Frantz, C., Hill, J. L., and Stamberg, J. Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. Am J Clin Oncol, 26: 300-306, 2003.
20. **Toretsky, J. A.**, Everly, E. M., Padilla-Nash, H. M., Chen, A., Abruzzo, L. V., Eskenazi, A. E., Frantz, C., Ried, T., and Stamberg, J. Novel Translocation in Acute Megakaryoblastic Leukemia (AML-M7). J Pediatr Hematol Oncol, 25: 396-402, 2003.
21. Uren, A., Merchant, M. S., Sun, C. J., Vitolo, M. I., Sun, Y., Tsokos, M., Illei, P. B., Ladanyi, M., Passaniti, A., Mackall, C., and **Toretsky, J. A.** Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene, 22: 2334-2342, 2003.
22. Gorlick, R., Anderson, P., Andrulis, I., Arndt, C., Beardsley, G. P., Bernstein, M., Bridge, J., Cheung, N. K., Dome, J. S., Ebb, D., Gardner, T., Gebhardt, M., Grier, H., Hansen, M., Healey, J., Helman, L., Hock, J., Houghton, J., Houghton, P., Huvos, A., Khanna, C., Kieran, M., Kleinerman, E., Ladanyi, M., Lau, C., Malkin, D., Marina, N., Meltzer, P., Meyers, P., Schofield, D., Schwartz, C., Smith, M. A., **Toretsky, J.**, Tsokos, M., Wexler, L., Wigginton, J., Withrow, S., Schoenfeldt, M., and Anderson, B. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary. Clin Cancer Res, 9: 5442-5453, 2003.
23. Gober, M. D., Smith, C. C., Ueda, K., **Toretsky, J. A.**, and Aurelian, L. Forced expression of the H11 heat shock protein can be regulated by DNA methylation and trigger apoptosis in human cells. J Biol Chem, 278: 37600-37609, 2003.
24. Zhang, H., Merchant, M. S., Chua, K. S., Khanna, C., Helman, L. J., Telford, B., Ward, Y., Summers, J., **Toretsky, J.**, Thomas, E. K., June, C. H., and Mackall, C. L. Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T Cells. Cancer Biol Ther, 2: 579-586, 2003.
25. **Jeffrey A. Toretsky**, Amy Levenson, Irvin N. Weinberg, Jonathan F. Tait, Aykut Üren, and Ronald C. Mease. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nuclear Medicine and Biology, 31(6):747-52, 2004.
26. Aykut Üren, Vladimir Wolf, Yu-Feng Sun, Amir Azari, Jeffrey S. Rubin, **Jeffrey A Toretsky**. Wnt/Frizzled Signaling in Ewing's Sarcoma. Pediatric Blood and Cancer, 43(3): 243-9, 2004.
27. Uren, A., Tcherkasskaya, O., and **Toretsky, J. A.** Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry, 43: 13579-13589, 2004.

28. French, C. A., Kutok, J. L., Faquin, W. C., **Toretsky, J. A.**, Antonescu, C. R., Griffin, C. A., Nose, V., Vargas, S. O., Moschovi, M., Tzortzatou-Stathopoulou, F., Miyoshi, I., Perez-Atayde, A. R., Aster, J. C., and Fletcher, J. A. Midline carcinoma of children and young adults with NUT rearrangement. *J Clin Oncol*, 22: 4135-4139, 2004.
29. Kitlinska, J., Abe, K., Kuo, L., Pons, J., Yu, M., Li, L., Tilan, J., Everhart, L., Lee, E. W., Zukowska, Z., and **Toretsky, J. A.** Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. *Cancer Res*, 65: 1719-1728, 2005.
30. Abaan, O. D., Levenson, A., Khan, O., Furth, P. A., Üren, A., and **Toretsky, J. A.** PTPL1 is a Direct Transcriptional Target of EWS/FLI1 and Modulates Ewing's Sarcoma Tumorigenesis. *Oncogene*, 24: 2715-2722, 2005.
31. Üren, A., Fallen, S., Yuan, H., Usubutun, A., Kucukali, T., Schlegel, R., and **Toretsky, J. A.** Activation of the Canonical Wnt Pathway during Genital Keratinocyte Transformation: A Model for Cervical Cancer Progression. *Cancer Res*, 65: 6199-6206, 2005.
32. Brooks, B. P., Meck, J. M., Haddad, B. R., Bendavid, C., Blain, D., and **Toretsky, J. A.** Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature. *BMC Med Genet*, 7: 2, 2006. PMID: PMC1379634
33. **Toretsky, J. A.**, Erkizan, V., Levenson, A., Abaan, O. D., Parvin, J. D., Cripe, T. P., Rice, A. M., Lee, S. B., and Uren, A. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. *Cancer Res*, 66: 5574-5581, 2006.
34. Kitlinska, J., Kuo, L., Abe, K., Pons, J., Yu, M., Li, L., Tilan, J., **Toretsky, J.**, and Zukowska, Z. Role of neuropeptide Y and dipeptidyl peptidase IV in regulation of Ewing's sarcoma growth. *Adv Exp Med Biol*, 575: 223-229, 2006.
35. Adhikari, S., **Toretsky, J. A.**, Yuan, L., and Roy, R. Magnesium, essential for base excision repair enzymes, inhibits substrate binding of N-methylpurine-DNA glycosylase. *J Biol Chem*, 281: 29525-32, 2006.
36. Aryee, D. N., Kreppel, M., Bachmaier, R., Uren, A., Muehlbacher, K., Wagner, S., Breiteneder, H., Ban, J., **Toretsky, J. A.**, and Kovar, H. Single-chain Antibodies to the EWS NH2 Terminus Structurally Discriminate between Intact and Chimeric EWS in Ewing's Sarcoma and Interfere with the Transcriptional Activity of EWS In vivo. *Cancer Res*, 66: 9862-9869, 2006.
37. French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, Kutok JL, **Toretsky JA**, Tadavarthy AK, Kees UR, Fletcher JA, Aster JC. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. *Oncogene*, 27(15):2237-42, 2008.
38. Endo Y, Beauchamp E, Woods D, Taylor WG, **Toretsky JA**, Uren A, Rubin JS. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. *Mol Cell Biol*, 28(7):2368-79, 2008. PMID: PMC2268413
39. Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, **Toretsky JA**, Uren A. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. *Pediatr Blood Cancer*, 51(3):349-55, 2008.
40. Beauchamp E, Bulut G, Abaan OD, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, **Toretsky JA**, Uren A. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. *J Biol Chem* 284(14):9074-82, 2009. PMID: PMC2666556
41. Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, **Toretsky JA**, Riegel AT, Wellstein A. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. *Oncogene*, 28(37):3296-306, 2009.

42. Raygada M, Arthur DC, Wayne AS, Rennert OM, **Toretsky JA**, Stratakis CA. Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia. *Pediatr Blood Cancer*, 2009. PMID: PMC2783853
43. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, **Toretsky JA**. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. *Nature Medicine*, 15(7):750-6, 2009. PMID: PMC2777681.
EDITOR'S CHOICE REVIEW IN SCIENCE, AUGUST 2009. FACULTY OF 1000 EXCEPTIONAL ARTICLE LIST WITH AN F1000 FACTOR SCORE OF 9.0.
44. Lu C, Everhart L, Tilan J, Kuo L, Sun CC, Munivenkatappa, R. B., Jonsson-Rylander, A. C., Sun, J., Kuan-Celarier, A., Li, L., Abe, K., Zukowska, Z., **Toretsky, J. A.**, Kitlinska, J. Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. *Oncogene* 29: 5630-5642, 2010. PMID: PMC2955165
45. Awad O, Yustein JT, Shah P, Gul N, Katuri V, Alison O'Neill, Yali Kong, Milton L. Brown, ***Jeffrey A. Toretsky**, *David M. Loeb. High ALDH Activity Identifies Chemotherapy-Resistant Ewing's Sarcoma Stem Cells That Retain Sensitivity to EWS-FLI1 Inhibition. *PLoS ONE* 5(11): e13943. 2010 * Co-senior authored. PMID: PMC2978678
46. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee, Y. C., Peaceman, D., Ozdemirli, M., Rodriguez, O., Macdonald, T. J., Albanese, C., **Toretsky, J. A.**, Uren, A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. *J Clin Invest* 121(1): 148-160, 2011. PMID: PMC3007144
47. Borinstein SC, Barkauskas DA, Krailo M, Scher D, Scher L, Schlottmann S, Kallakury B, Dickman PS, Pawel BR, West DC, Womer RB, **Toretsky JA**. Investigation of the Insulin-Like Growth Factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group. *Cancer* 117(21):4966-76, 2011.
48. Rahim S, Beauchamp EM, Kong Y, Brown ML, **Toretsky JA**, Üren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. *PLoS One*. 2011 Apr 29;6(4):e19343. PMID: PMC3084826
49. Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, Jeha D, Hanafy J, Lee CK, Sun J, Izycka-Swieszczewska E, **Toretsky JA**, Kitlinska J. Dipeptidyl peptidases as survival factors in Ewing's sarcoma family of tumors: implications for tumor biology and therapy. *J Biol Chem*. 2011 Aug 5;286(31):27494-505.. PMID: PMC3149342
50. Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, **Toretsky JA**, Khanna C, Uren A. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. *Oncogene* 31(3):269-81, 2012. PMID: PMC3513970
51. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, **Toretsky J**, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. *Science* 333(6045):1039-43, 2011. PMID: PMC3374335
52. Erkizan HV, Scher LJ, Gamble E, Barber-Rotenberg JS, Sajwan KP, Üren A, **Toretsky JA**. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. *Cell Cycle* 10(19):3397-408, 2011. PMID: PMC3233630
53. Gülay Bulut, Shannon Fallen, Elspeth Beauchamp, Lauren Elizabeth Drebing, Junfeng Sun, Deborah L. Berry, Bhaskar Kallakury, Christopher P. Crum, **Jeffrey A. Toretsky**, Richard Schlegel, Aykut Üren: Beta-Catenin Accelerates Human Papilloma Virus Type-16 Mediated Cervical Carcinogenesis in Transgenic Mice. *PLoS ONE* 6(11): e27243, 2011. PMID: PMC3210148

54. Ringer L, Sirajuddin P, Heckler M, Ghosh A, Supryniewicz F, Yenugonda VM, Brown ML, **Toretsky JA**, Uren A, Lee Y, Macdonald TJ, Rodriguez O, Glazer RI, Schlegel R, Albanese. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther. 12(9):818-26, 2011. PMID: PMC3367670
55. Scott Grindrod, Simeng Suy, Shannon Fallen, Masumi Eto, **Jeffery Toretsky**, Milton L. Brown. Effects of a Fluorescent Myosin Light Chain Phosphatase Inhibitor on Prostate Cancer Cells. Front Oncol 1:27, 2011. PMID: PMC3356144
56. Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, **Toretsky JA**, Houghton PJ. Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer 59(4): 753–755, 2012. PMID: PMC3612422
57. Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, Kobs CL, South NL, Summer S, Monroe PJ, Chruszcz M, Dobrev V, Tosso PN, Scher LJ, Minor W, Brown ML, Metallo SJ, Üren A, **Toretsky JA**. Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1. Oncotarget 3(2):172-82, 2012. PMID: PMC3326647
58. Heinrich Kovar, Javier Alonso, Pierre Aman, Dave N.T. Aryee, Jozef Ban, Sue Burchill, Stefan Burdach, Enrique De Alava, Olivier Delattre, Uta Dirksen, Argyro Fourtouna, Simone Fulda, Lee J. Helman, David Herrero-Martin, Pancras C.W. Hogendoorn, Udo Kontny, Elizabeth R. Lawlor, Stephen L. Lessnick, Antonio Llombart-Bosch, Markus Metzler, Richard Moriggl, Stephan Niedan, Jenny Potratz, Françoise Redini, Günther H.S. Richter, Lucia T. Riedmann, Claudia Rossig, Beat W. Schäfer, Raphaela Schwentner, Katia Scotlandi, Poul H. Sorensen, Martin S. Staeger, Franck Tirede, **Jeffrey Toretsky**, Selena Ventura, Angelika Eggert, Ruth Ladenstein. The First European Interdisciplinary Ewing sarcoma research summit. Frontiers in Pediatric Oncology. 2:54, 2012. Epub 2012 May 29. PMID: PMC3361960
59. Schlottmann S, Erkizan HV, Barber-Rotenberg JS, Knights C, Cheema A, Üren A., Avantaggiati ML, **Toretsky, JA**. Acetylation increases EWS-FLI1 DNA binding and transcriptional activity. Frontiers in Pediatric Oncology 2:107, 2012. PMID: PMC3435532
60. Ogan D Abaan, Wiljan Hendriks, Aykut Üren, **Jeffrey A. Toretsky**, Hayriye V Erkizan. Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1. Experimental Cell Research 319(1): 1-11, 2013. PMID: PMC3638858
61. Kirilyuk A, Shimoji M, Catania J, Sahu G, Pattabiraman N, Giordano A, Albanese C, Mocchetti I, **Toretsky JA**, Uversky VN, Avantaggiati ML. An Intrinsically Disordered Region of the Acetyltransferase p300 with Similarity to Prion-Like Domains Plays a Role in Aggregation. PLoS One 7(11):e48243, 2012. PMID: PMC3486812
62. Alison O'Neill, Nilay Shah, Naamah Zitomersky, Marc Ladanyi, Neerav Shukla, Aykut Üren, David Loeb, and **Jeffrey Toretsky**. Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature. Sarcoma. 2013: 450478 PMID: PMC3569907
63. Lee HJ, Yoon C, Schmidt B, Park do J, Zhang AY, Erkizan HV, **Toretsky JA**, Kirsch DG, Yoon SS. Combining PARP-1 inhibition and radiation in ewing sarcoma results in lethal DNA damage. Mol Cancer Ther. 2013 Nov;12(11):2591-600.

64. Paige M, Kosturko G, Bulut G, Miessau M, Rahim S, **Toretsky JA**, Brown ML, Uren A. Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma. Bioorg Med Chem. 2014 Jan 1;22(1):478-87.
65. Tilan JU, Lu C, Galli S, Izycka-Swieszewska E, Earnest JP, Shabbir A, Everhart LM, Wang S, Martin S, Horton M, Mahajan A, Christian D, O'Neill A, Wang H, Zhuang T, Czarnecka M, Johnson MD, **Toretsky JA**, Kitlinska J. Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects. Oncotarget. 2013 Dec;4(12):2487-501.
66. Sung-Hyeok Hong, Sarah. E. Youbi, S. Peter Hong, Bhaskar Kallakury, Phillip Monroe, Hayriye V Erkizan, Julie S. Barber-Rotenberg, Peter Houghton, Aykut Üren, **Jeffrey A. Toretsky**. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget. 2014 Jan; 5(2):338-50.
67. Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, **Toretsky JA**. Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer. 2014 Apr;61(4):749-52.
68. Carmody Soni EE, Schlottman S, Erkizan HV, Uren A, **Toretsky JA**. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma. Clin Orthop Relat Res. 2014 Mar;472(3):874-82.
69. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, **Toretsky J**, Wellstein A, Yi C. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Science Signaling. 2014 May 6;7(324):ra42. PMC:4175524
70. Rahim S, Minas T, Hong SH, Justvig S, Celik H, Kont YS, Han J, Kallarakal AT, Kong Y, Rudek MA, Brown ML, Kallakury B, **Toretsky JA**, Uren A. A Small Molecule Inhibitor of ETV1, YK-4-279, Prevents Prostate Cancer Growth and Metastasis in a Mouse Xenograft Model. PLoS ONE. 2014;9(12):e114260. PMC:4257561
71. Shah N, Wang J, Selich-Anderson J, Graham G, Siddiqui H, Li X, Khan J, **Toretsky J**. PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-cis Retinoic Acid-Mediated Differentiation in Neuroblastoma. Clin Cancer Res. 2014 Aug 15;20(16):4400-12. PMC:4134768
72. Tosso PN, Kong Y, Scher L, Cummins R, Schneider J, Rahim S, Holman KT, **Toretsky J**, Wang K, Uren A, Brown ML. Synthesis and Structure-Activity Relationship Studies of Small Molecule Disruptors of EWS-FLI1 Interactions in Ewing's Sarcoma. J Med Chem. 2014 Dec 26;57(24):10290-303. PMC:4281097
73. Tilan JU, Krailo M, Barkauskas DA, Galli S, Mtaweh H, Long J, Wang H, Hawkins K, Lu C, Jeha D, Izycka-Swieszewska E, Lawlor ER, **Toretsky JA**, Kitlinska JB. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival. Cancer. 2015 Mar 1;121(5):697-707. PubMed PMID: 25387699. Pubmed Central PMCID: 4339539.
74. Erkizan HV, Schneider JA, Sajwan K, Graham GT, Griffin B, Chasovskikh S, Youbi SE, Kallarakal A, Chruszcz M, Padmanabhan R, Casey JL, Uren A, **Toretsky JA**. RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1. Nucleic Acids Res. 2015 Jan;43(2):1069-80. PubMed PMID: 25564528. Pubmed Central PMCID: 4333382.
75. Hong SH, Tilan JU, Galli S, Izycka-Swieszewska E, Polk T, Horton M, Mahajan A, Christian D, Jenkins S, Acree R, Connors K, Ledo P, Lu C, Lee YC, Rodriguez O, **Toretsky JA**, Albanese C, Kitlinska J. High neuropeptide Y release associates with

- Ewing sarcoma bone dissemination - in vivo model of site-specific metastases. *Oncotarget*. 2015 Mar 30;6(9):7151-65. PubMed PMID: 25714031. Pubmed Central PMCID: 4466675.
76. Celik H, Hong SH, Colon-Lopez DD, Han J, Kont YS, Minas TZ, Swift M, Paige M, Glasgow E, **Toretsky JA**, Bosch J, Uren A. Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box. *Mol Cancer Ther*. 2015 Nov;14(11):2497-507. PubMed PMID: 26358752. Pubmed Central PMCID: 4636458.
77. Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH, Jr., Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, **Toretsky JA**, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML. The genomic landscape of juvenile myelomonocytic leukemia. *Nat Genet*. 2015 Nov;47(11):1326-33. PubMed PMID: 26457647. Pubmed Central PMCID: 4626387.
78. Minas TZ, Han J, Javaheri T, Hong SH, Schleder M, Saygideger-Kont Y, Celik H, Mueller KM, Temel I, Ozdemirli M, Kovar H, Erkizan HV, **Toretsky J**, Kenner L, Moriggl R, Uren A. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. *Oncotarget*. 2015 Nov 10;6(35):37678-94. PubMed PMID: 26462019. Pubmed Central PMCID: 4741957.
79. Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grunewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Redini F, Richter GH, Rossig C, Schadler K, Schafer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Suzhai K, Tirado OM, Tirode F, **Toretsky J**, Tsafou K, Uren A, Zinovyev A, Delattre O. The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. *Oncotarget*. 2016 Feb 23;7(8):8613-24. PubMed PMID: 26802024.
80. Saygideger-Kont Y, Minas TZ, Jones H, Hour S, Celik H, Temel I, Han J, Atabey N, Erkizan HV, **Toretsky JA**, Uren A. Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non-Small Cell Lung Cancer Cells. *Neoplasia*. 2016 Feb;18(2):111-20. PubMed PMID: 26936397.

Peer-Reviewed Reviews

1. **Toretsky, JA** and Helman LJ. Insulin-like Growth Factor II and Human Cancer. *Journal of Endocrinology* 149(3): 367-372, 1996.
2. **Toretsky, JA** and Helman, LJ. Cytogenetics and Experimental Models *in Current Opinion in Oncology*, Sarcomas, ed Holcombe Grier, Rapid Science Press, 342-7, 1997.
3. **Toretsky, JA**. Insulin-like Growth Factor Type-I Receptor Signaling. *Cancer Research Alert*, Cover Article, June 2000.
4. Üren, A. and **Toretsky, J. A**. Pediatric malignancies provide unique cancer therapy targets. *Curr Opin Pediatr*, 17: 14-19, 2005.
5. Üren, Aykut and **Toretsky, Jeffrey A**. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. *Future Oncology*, 1(4):521-528, 2005.

6. Abaan OD, **Toretsky JA**. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev, 27(2):205-14, 2008.
7. Kim SY, **Toretsky JA**, Scher D, Helman LJ. The Role of IGF-1R in Pediatric Malignancies. Oncologist, 2009. PMID: PMC2721475
8. Hayriye V. Erkizan, Vladimir N. Uversky, **Jeffrey A. Toretsky**, Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma. Clin Cancer Res 16, 4077-4083, 2010.
9. **Toretsky JA**, Wright PE. Assemblages: Functional units formed by cellular phase separation. J Cell Biol. 2014 Sep 1;206(5):579-88.
10. Zollner SK, Rossig C, Toretsky JA. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer. Cancer Metastasis Rev. 2015 Sep;34(3):417-28. PubMed PMID: 26277104.

Invited Commentary

Toretsky, Jeffrey A and Gorlick, Richard. IGF-1R targeted treatment of sarcoma. Lancet Oncology, 11(2): 105-106, 2010.

Wellstein A, **Toretsky JA**. Hunting ALK to feed targeted cancer therapy. Nat Med. 2011 Mar;17(3):290-1.

Book and Online Chapters

Gorlick, R, **Toretsky, J**, Teot, L, Bernstein, M. "Bone Tumors", in Holland and Frei Cancer Medicine, 7th edition, Editors Kufe, Pollack, Weichselbaum, Bast, Gansler, Holland, and Frei, April 2006.

Gorlick, R, **Toretsky, J**, Teot, L, Bernstein, M. "Bone Tumors," in Holland and Frei Cancer Medicine, 6th edition, Editors Kufe, Pollack, Weichselbaum, Bast, Gansler, Holland, and Frei, April 2003.

Toretsky, J. "Ewing Sarcoma and Primitive Neuroectodermal Tumors." Epeditrics, Emedicine, 2001, Updates 2005, 2007, 2008, 2012, 2014. <http://www.epeditrics.com>. 11,543 page views as of 1/26/10.

Jeffrey A. Toretsky, Heinrich Kovar, Michael Paulussen, R. Lor Randall, Andreas Schuck, Lisa A. Teot, Herbert Jurgens and Mark Bernstein. Ewing's Sarcoma Family of Tumors, in Cancer in Children, 1st edition, Editor William Carroll, Jones and Bartlett Publishers, 2007.

Toretsky, Jeffrey A. and Uren, Aykut. "Ewing's Sarcoma Family of Tumors: Molecular Targets Need Arrows," in Molecularly Targeted Therapy for Childhood Cancer, 1st Edition, Editors, Peter Houghton and Robert Arceci, Springer Science and Business Media, 2010.

Toretsky, Jeffrey A and Mackall, Crystal. "Ewing's Sarcoma Family of Tumors", in Rudolph's Pediatrics, Editors, Colin D. Rudolph, et al., McGraw Hill Medical, 2010.

Toretsky, Jeffrey A., Heinrich Kovar, Michael Paulussen, R. Lor Randall, Andreas Schuck, Lisa A. Teot, Herbert Jurgens and Mark Bernstein. "Ewing's Sarcoma Family of Tumors." Cancer in Children and Adolescents. Ed. William L Carroll and Jonathan L Finlay. Sudbury, Mass.: Jones and Bartlett Publishers, 2010. 395-408.

Jeffrey A. Toretsky and Aerang Kim. “ Pediatric Solid Tumors: Embryonal Cell Oncogenesis”. in *Molecular Oncology: Causes of Cancer and Targets for Treatment.*, edited by Edward Gelmann, Charles Sawyers, and Frank Rauscher III. Cambridge University Press, 826-35, 2014.

Meeting Abstracts

1. **Toretsky, JA**, Shahidi, NT, Finlay, JL. Effects of Human Interferon Gamma on Human Hematopoietic Progenitor Cells. International Society of Experimental Hematology, August 1984.
2. Finlay, JL, **Toretsky, JA**, Hoffman, R, Bruno, E, Shahidi, NT. Cyclosporine A in Refractory Aplastic Anemia. American Society of Hematology, December 1984.
3. **Toretsky, JA**, Whitesell, L, Neckers, LM. Use of Geldanamycin to Study Early Activation Events in Normal Lymphocytes. *Molecular Basis of Cancer*. June 1993.
4. **Toretsky, JA**, Bhat, NK, Neckers, LM. Inhibition of EWS-ERG-B Protein Alters Tumor Growth of Peripheral Primitive Neuroectodermal Tumors in Athymic Mice. *Molecular Basis of Cancer*, June 1994.
5. **Toretsky, JA**, Neckers, L, Wexler, LH. Minimal Residual Disease in the Ewing's Sarcoma Family of Tumors: Evaluation of Peripheral Blood Progenitor Cells. Abstract. American Society of Pediatric Hematology/Oncology. October 1994.
6. **Toretsky, JA**, Connell, Y, Neckers, L, Bhat, NK. Inhibition of EWS-FLI-1 Fusion Protein with Antisense Oligodeoxynucleotides. *Biochemistry of Neuroectodermal Tumors*, Rome Italy, June 1995.
7. **Toretsky, JA**, Bachman, C, Kalebic, T, Blakesley, V, LeRoith, D, Helman, L. Insulin-like Growth Factor-I Receptor is Necessary for EWS/FLI-1 Induced Transformation of Fibroblasts. *Transcription Factors in Cancer*. American Association of Cancer Research, January 1997.
8. Blakesley, V, Helman, L, Kalebic, T, LeRoith, D, **Toretsky, JA**. Insulin-like Growth Factor-I Receptor is Necessary for EWS/FLI-1 Induced Transformation of Fibroblasts. American Society of Pediatric Hematology/Oncology, Chicago, IL, October 1996.
9. **Toretsky, JA**, and Helman, L. Cytokine Regulators of Ewing's Family of Tumors Growth: Is there an Autocrine Loop? American Society of Pediatric Hematology/Oncology, San Francisco, CA, September 1997.
10. Wang, S., Zou, T-T., Kong, D., Huang, J., Souza, R., Smolinski, K., Abraham, J., Meltzer, S., **Toretsky, J**. Growth Inhibition and Apoptotic Cell Death in Colorectal Cancer Cells Induced by Blocking IGFIR or its Signal Transduction. American Association for Cancer Research, New Orleans, LA, April 1998.
11. **Toretsky, JA**, Helman, LJ, Steinberg, S, Parente, C, Counts, D, Piromis, B, Thakar, M, Eskenazi, A, Wexler, L. IGF-I and Apoptosis in the Ewing's Sarcoma Family of Tumors. American Society of Clinical Oncology, Atlanta GA., May 1999.
12. Thakar, M., Gutkind, S., Eskenazi, A., **Toretsky, JA**. Akt enables Ewing's Sarcoma Family of Tumors to survive doxorubicin therapy. American Association of Cancer Research, Philadelphia, PA., April 1999.
13. Thakar, M., Eskenazi, A., **Toretsky, JA**. Blockade of phosphoinositide 3-OH kinase enhances doxorubicin in Ewing's Sarcoma Family of Tumors. Society Internationale Oncologie Pediatric/American Society of Pediatric Hematology and Oncology, Montreal, CA., September 1999.
14. Rapoport, A, Simons-Evelyn, M, Bailey-Dell, K, **Toretsky, JA**, Ross, D, Fenton, R, Kalvakolanu, D. PBK/TOPK-A novel mitotic kinase is upregulated in Burkitt's Lymphoma and other Neoplastic cell lines. American Society of Hematology, December 2000.

15. **Toretsky, Jeffrey A**; Uren, Aykut; Mullholland, Justin; Rao, Srinavas; Thakar, Manjusha; Skervsky, Amy; Mease, Ronnie. Noninvasive in vivo cell death detection in Ewing's Sarcoma. American Association for Cancer Research, New Orleans, LA, March 2001.
16. **Toretsky, Jeffrey A**; Uren, Aykut; Mullholland, Justin; Rao, Srinavas; Thakar, Manjusha; Skervsky, Amy; Weinberg, Irving, Line, Bruce, Mease, Ronnie. Non-invasive Detection of Ewing's Sarcoma Cell Death In Vivo. American Society of Pediatric Hematology and Oncology/Society for Pediatric Research, Baltimore, MD, April 2001.
17. **J. Toretsky**, M. Thakar, A. Uren, A. Rice, T. Cripe Transcriptional modeling of EWS/FLI1: a key to unlocking function. Brisbane, Australia, October 2001.
18. Aykut Üren, Amir A. Azari, Cassandra Berrian, Vladimir Wolf, Jeffrey S. Rubin, **Jeffrey A. Toretsky**. Wnt/Frizzled Signaling in Ewing's Sarcoma. Keystone Symposia, Taos, NM, March 2002.
19. Aykut Uren, Chen-Chih J Sun, Michelle Vitolo, Yu-Feng Sun, Maria Tsokos, Antonino Passaniti, **Jeffrey A Toretsky**. Expression of Functional Beta-PDGF Receptors by Ewing's Sarcoma. American Association for Cancer Research, San Francisco, CA, April 2002.
20. R.C. Mease*, I.N. Weinberg, **J. Toretsky**, J.F. Tait. Preparation of F-18 Labeled Annexin V: A Potential Pet Radiopharmaceutical For Imaging Cell Death. J. Nucl. Med. 44:295P Society for Nuclear Medicine, New Orleans, LA, June 2003.
21. J. Kitlinska, **J. Toretsky**, Z. Zukowska. Neuropeptide Y (NPY) and dipeptidyl peptidase IV (DPPIV) inhibitor decrease Ewing's sarcoma growth and enhance apoptosis. American Society for Cell Biology, San Francisco, CA, December 2003.
22. Ogan D. Abaan, Amy Levenson, Aykut Uren, **Jeffrey A. Toretsky**. The protein tyrosine phosphatase PTPL1 modulates Ewing's sarcoma tumorigenesis. American Association for Cancer Research, Orlando, FL, March 2004.
23. J. Kitlinska, **J. Toretsky**, Z. Zukowska. NPY and Growth of Neural-Crest Derived Tumors: Differential Proliferative Effects and Angiogenesis. 7th International NPY Meeting, Coimbra, Portugal, 2004.
24. **Jeffrey A. Toretsky**, Ogan D. Abaan, Amy Levenson, Aykut Uren. The protein tyrosine phosphatase PTPL1 modulates Ewing's sarcoma tumorigenesis. Protein Phosphatases. FASEB Meeting, Snomass, CO, 2004.
25. Kitlinska J., **Toretsky J.**, Pons J., Zukowska Z.: Proliferative effects of neuropeptide Y (NPY) on neuroblastoma cells: synergistic interactions of multiple receptors. Experimental Biology 2004, Washington, DC.
26. Kitlinska, J., Abe K., Kuo L., Pons, J., Yu, M., Li, L., Tilan J., Everhart L., Lee, E.W., **Toretsky, J.A.**, Zukowska Z.. Role of neuropeptide Y and dipeptidyl peptidase IV in regulation of growth of Ewing's sarcoma family of tumors. Oral presentation at the 2nd International Conference on Dipeptidyl Aminopeptidases, Magdeburg, Germany, 2005.
27. Kitlinska, J., Abe K., Kuo L., Pons, J., Yu, M., Li, L., Tilan, J., Zukowska, Z., **Toretsky, J.** Neuropeptide Y in neural crest-derived pediatric tumors – effect on growth and vascularization. Pediatric Academic Societies' Annual Meeting, Washington, DC, May 2005.
28. Ogan D. Abaan, Judy Quong, Andrew Quong, Aykut Üren, **Jeffrey A. Toretsky**. PTPL1 is a Transcriptional Target of the Oncogenic Fusion Protein EWS-FLI1 And May Modulate IGF-IR Signaling. Protein Phosphorylation & Cell Signaling, Cold Spring Harbor, NY, 2005.
29. Ogan D. Abaan, Amy Levenson, Aykut Üren, **Jeffrey A. Toretsky**. The Protein Tyrosine Phosphatase PTPL1 Modulates Ewing's Sarcoma Tumorigenesis. Pediatric Academic Societies Annual Meeting, Washington, DC, 2005.

30. Hayriye Verda Erkizan, Ogan D. Abaan, Aykut Uren, **Jeffrey A. Toretsky**. RNA Helicase A As A Partner Of EWS-FLI1 Protein In Ewing's Sarcoma Cell Lines. PAS Meeting, Washington DC, 2005.
31. **Jeffrey A. Toretsky**, Hayriye Erkizan, Ogan D. Abaan, Amy Levenson, Aykut Uren. RNA Helicase A Is A Functional Partner Of EWS-FLI1 In Ewing's Sarcoma Family Of Tumors. Helicases And NTP Driven Nucleic Acid Machines, Arolla Switzerland 2005.
32. Laura Kelsey McCarty, Sunil Mandal, Alan Kozikowski, **Jeffrey Toretsky**. Select phosphoinositol analogs reduce Ewing's sarcoma and leiomyosarcoma cell line growth. AACR Molecular Targets and Cancer Therapeutics Meeting, Philadelphia, PA, 2005.
33. Hayriye Verda Erkizan, Ogan D. Abaan, Aykut Üren, **Jeffrey A. Toretsky**. RNA Helicase A (RHA) Is A Functional Partner Of EWS-FLI1 In Ewing's Sarcoma Family Of Tumors. AACR Meeting Washington DC, 2006.
34. Shannon Fallen, Richard Schlegel, Elaine Fuchs, **Jeffrey A. Toretsky**, Aykut Üren. Transgenic Mouse Models of Skin and Cervical Tumor Development Involving Beta-catenin. Keystone Symposia, Wnt Meeting, Snowbird, Utah, 2006.
35. **Jeffrey A. Toretsky**, Verda Erkizan, Ogan D. Abaan, and Aykut Üren. Ewing sarcoma oncoprotein EWS-FLI1 activity is enhanced by RNA helicase a (RHA). 31st FEBS Congress, Molecules in Health and Disease, Istanbul, Turkey, 2006.
36. Kitlinska, J., Kuo, L., Tilan, J., Abe, K., Everhart, L., Li, L., **Toretsky, J.**, Zukowska, Z. Neuropeptide Y in neuroblastoma – effect on growth and vascularization. Oral presentation at 8th NPY Meeting April 22-26, 2006 St. Petersburg, FL.
37. Kitlinska, J., Kuo, L., Tilan, J., Abe, K., Everhart, L., Li, L., Sun, C., Zukowska, Z. and **Toretsky, J.**, “Neuropeptide Y – a novel growth factor for neuroblastoma.” Advances in Neuroblastoma Research Meeting, Los Angeles, CA, 2006.
38. Ogan D. Abaan, Sarah Pickard, Aykut Üren, **Jeffrey A. Toretsky**. Ikba May Be A Physiological Target Of Protein Tyrosine Phosphatase L1 (PTPL1) In Ewing's Sarcoma. Protein Phosphatases. FASEB Meeting, Snowmass, CO, 2006.
39. Hayriye Verda Erkizan, Silke Schlottmann, L. Kelsey Mccarty, Shannon Fallen, Ogan D. Abaan, Aykut Üren, **Jeffrey A. Toretsky**. RNA Helicase A (RHA) Enhances The Oncogenic Function Of EWS-FLI1 In Ewing's Sarcoma. Symposium On Biological Complexity: “Disease Of Transcription”, Salk Institute, San Diego, California, January 11-14, 2007.
40. Endo Y, Beauchamp EM, **Toretsky JA**, Üren A, Rubin JS. Wnt-3a stimulates neurite outgrowth in Ewing sarcoma cells. WNT 2007 Conference, University of California San Diego, La Jolla, California, June 21-23, 2007
41. L. Kelsey McCarty, Pavel A. Petukhov, Sunil K. Mandal, Silke Schlottmann, Verda Erkizan, Aykut Uren, Alan P. Kozikowski, **Jeffrey A. Toretsky**. Novel small molecule inhibitors of Akt reduce Ewing's sarcoma cell growth. ASPHO Meeting, Toronto, CANADA, 2007.
42. **Jeffrey Toretsky**, Hayriye Verda Erkizan, Silke Schlottmann, Shannon Fallon, Ogan D. Abaan, Milton Brown, Aykut Uren. Therapeutic targeting of EWS-FLI1: Inhibition of Ewing's Sarcoma growth using peptides and small molecule lead compounds. Connective Tissue Oncology Society, Seattle, Washington, November 1-3, 2007. WON BEST POSTER AWARD.
43. Chen K, Fallen S, Abaan HO, **Toretsky JA**, Üren A. Wnt10b Induces chemotaxis of osteosarcoma and correlates with reduced survival. 13th annual Connective Tissue Oncology Society (CTOS) Meeting, Seattle, Washington, November 1-3, 2007.

44. Chen K, Fallen S, Abaan HO, **Toretsky JA**, Üren A. Wnt10b induces chemotaxis of Osteosarcoma and correlates with reduced survival. Wnt/beta-Catenin Signaling. Keystone, Colorado. Feb 17 - Feb 22, 2008.
45. Fallen S, Bulut G, **Toretsky J**, Üren A. Beta-catenin enhances HPV-E7 induced tumorigenesis. Signaling Pathways in Cancer and Development. Steamboat Springs, Colorado. March 24 - 29, 2008.
46. Bulut G, Beauchamp EM, Fallen S, Chen K, **Toretsky JA**, Khanna C, Üren A. Molecular targeting of ezrin as an anti-metastatic agent. TASSA Annual conference, Harvard University, Boston, Massachusetts. April 11-13, 2008
47. Hayriye Verda Erkizan, Silke Schlottmann, Shannon Fallon, Ogan D. Abaan, Milton Brown, Aykut Uren, **Jeffrey Toretsky**. Inhibition of Ewing's Sarcoma growth using peptides and small molecule lead compounds. American Association of Cancer Research, San Diego, CA, April 2008. ORAL PRESENTATION.
48. Yali Kong, Julie S. Barber, Hayriye V. Erkizan, Melinda Merchant, Tsu-hang Chou, **Jeffrey A. Toretsky**, Milton L. Brown. Synthesis and optimization of small molecule inhibitors of EWS-FLI1. 236th ACS National Meeting, Philadelphia, PA, United States, August 17-21, 2008.
49. **Jeffrey A Toretsky**, Hayriye Verda Erkizan, Silke Schlottmann, Yali Kong, Melinda Merchant, Milton Brown, Aykut Uren Inhibition of Ewing's Sarcoma Growth Via Therapeutic Targeting of EWS-FLI1. National Academy Keck Futures Initiative, Irvine, CA November 2008.
50. **Toretsky JA**, Erkizan HV, Schlottmann S, Kong Y, Merchant M, Brown M, Üren A. Inhibition of Ewing's Sarcoma Growth Using Therapeutic Targeting of EWS-FLI1. AACR, Translational Cancer Medicine 2008: Bridging the Lab and the Clinic in Cancer Medicine, November 3-6, 2008, Jerusalem, Israel.
51. Bulut G, Chen K, Glasgow E, Hong HS, Lee HS, **Toretsky JA**, Daar I, Khanna C, Üren A. Small Molecule Inhibitors of Ezrin as Anti-Metastatic Agents in Osteosarcoma. 100th AACR Annual Meeting, Denver, CO, April 17-22, 2009
52. Bulut G, Fallen S, Sun J, Kallakury B, **Toretsky JA**, Schlegel R, Üren A. Beta-catenin Accelerates Human Papilloma Virus Type-16 Mediated Cervical Carcinogenesis WNT 2009 Meeting, Georgetown University, Washington DC, June 11-14, 2009
53. **J Toretsky**; H Verda Erkizan; Y Kong; M Merchant; J Barber-Rotenberg; M Brown; A Uren. Therapeutic Targeting of EWS-FLI1: Small Molecule Protein-Protein Interaction Inhibitors Prevent Xenograft Growth. Connective Tissue Oncology Society, Miami, FL, 11/6/09 (Oral Presentation).
54. G Bulut; K Chen; E Glasgow; S Hong; H Lee; **J Toretsky**; I Daar; C Khanna; A Uren Small molecule inhibitors of ezrin as anti-metastatic agents in osteosarcoma. Connective Tissue Oncology Society, Miami, FL, 11/7/09.
55. Barber-Rotenberg JS, Kong Y, Schnure N, Dakshanamurthy S, Frazier P, Erkizan HV, Brown ML, Uren A, and **Toretsky JA**. EWS-FLI1 as a molecular target: Identification of inhibitors for a disordered protein. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting, Boston, MA. November 15-19, 2009.
56. Julie S. Barber-Rotenberg, Yali Kong, Nilan Schnure, Sivanesan Dakshanamurthy, Peter Frazier, Hayriye V. Erkizan, Milton L. Brown, Aykut Uren, **Jeffrey A. Toretsky**. EWS-FLI1 as a molecular target: Small molecule inhibitors for a disordered protein. American Association of Cancer Research, Washington, DC, April 2010.
57. Elspeth M. Beauchamp, Olga Rodriguez, Christopher Albanese, **Jeffrey A. Toretsky**, and Aykut Üren. Arsenic Trioxide inhibits Ewing Sarcoma growth by blocking

Hedgehog/GLI pathway. American Association of Cancer Research, Washington, DC, April 2010.

58. Gulay Bulut, Kevin Chen, Eric Glasgow, Sung-Hyeok Hong, Hyun-Shik Lee, **Jeffrey A. Toretsky**, Ira Daar, Chand Khanna, Aykut Uren. Small molecule inhibitors of ezrin as anti-metastatic agents in osteosarcoma. American Association of Cancer Research, Washington, DC, April 2010.
59. Lauren M. Jacobwitz, Hayriye V. Erkizan, Aykut Üren, **Jeffrey A. Toretsky**. Phage display identifies novel toxic binding peptides for the disordered oncoprotein EWS-FLI1. American Association of Cancer Research, Washington, DC, April 2010.
60. Silke Schlottmann, Hayriye Verda Erkizan, Julie Barber-Rotenberg, Aykut Uren, Maria-Laura Avantaggiati, **Jeffrey A. Toretsky**. EWS-FLI1 is regulated by acetylation. American Association of Cancer Research, Washington, DC, April 2010.
61. **Jeffrey A. Toretsky**, Hayriye V. Erkizan, Yali Kong, Melinda Merchant, Julie S. Barber-Rotenberg, Milton L. Brown, Aykut Üren. Targeting of EWS-FLI1 with small molecule YK-4-279 reduces xenograft growth by disruption of disordered protein-protein interactions. American Association of Cancer Research, Washington, DC, April 2010.
62. Anna Kuan-Celarier, Congyi Lu, Lindsay Everhart, **Jeffrey A. Toretsky**, Joanna Kitlinska. Neuropeptide Y in neuroblastoma – interactions with BDNF and effect on cell survival. Advances in Neuroblastoma Research Association, June 2010.
63. Barber-Rotenberg JS, Kong Y, Tosso PN, Dakshanamurthy S, Erkizan HV, Brown ML, Uren A, **Toretsky JA**. EWS-FLI1 as a Molecular Target: Inhibitors for a Disordered Protein. Gordon Research Conference: Intrinsically Disordered Proteins. Davidson, North Carolina, July 11-16, 2010.
64. **Jeffrey A Toretsky**, Hayriye Verda Erkizan, Yali Kong, Melinda Merchant, Vladimir N. Uversky, Julie S. Barber-Rotenberg, Silke Schlottmann, Milton Brown, Aykut Üren. Targeting of EWS-FLI1 with small molecule YK-4-279 reduces xenograft growth by disruption of disordered protein-protein interactions Gordon Research Conference: Intrinsically Disordered Proteins, Davidson, North Carolina, July 11-16, 2010.
65. Hayriye V. Erkizan, Lauren M. Scher, S. Ellen Gamble, Julie Barber-Rotenberg, Aykut Üren, **Jeffrey A Toretsky**. Novel peptide directed targeting of EWS-FLI1 impairs tumor cell growth. American Association of Cancer Research, Orlando, FL, April 2011.
66. Said Rahim, Elspeth M. Beauchamp, Yali Kong, Milton L. Brown, **Jeffrey A. Toretsky**, Aykut Üren. YK4279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. American Association of Cancer Research, Orlando, FL, April 2011.
67. Gülay Bulut, Shannon Fallen, Elspeth M. Beauchamp, Lauren E. Drebing, Junfeng Sun, Deborah L. Berry, Bhaskar Kallakury, Christopher P. Crum, **Jeffrey A. Toretsky**, Richard Schlegel, Aykut Üren. Beta-catenin accelerates human papillomavirus type16 -E7 mediated cervical carcinogenesis in transgenic mice. American Association of Cancer Research, Orlando, FL, April 2011.
68. Gülay Bulut, Sung-Hyeok Hong, Kevin Chen, Said Rahim, George W. Kosturko, Elspeth M. Beauchamp, Eric Glasgow, **Jeffrey A. Toretsky**, Chand Khanna, Aykut Uren. Development of small molecules to target ezrin as anti-metastatic agents. American Association of Cancer Research, Orlando, FL, April 2011.
69. **Jeffrey A Toretsky**, Hayriye Verda Erkizan, Julie Barber-Rotenberg, Yali Kong, Milton Brown, Aykut Uren. YK-4-279 is a novel small molecule directly targets EWS-FLI1. American Society of Pediatric Hematology/Oncology Annual Meeting, Baltimore, MD April 14-17, 2011 (oral presentation).
70. **Jeffrey A Toretsky**, Hayriye Verda Erkizan, Julie S. Barber-Rotenberg, Aykut Üren. Recognizing Intrinsic Protein Disorder in Small Molecule Therapeutic Development.

National Cancer Institute Translational Science Meeting, Washington, DC, July 28-29, 2011 (oral presentation).

71. Ryan Commins, Aykut Üren, **Jeffrey Toretsky**. Combinations of current chemotherapies with YK-4-279 in Ewing sarcoma. Combined Musculoskeletal Tumor Society/Connective Tissue Oncology Society Meeting, Chicago, IL, October 26-29, 2011 (oral presentation).
72. Hayriye V. Erkizan, Lauren M. Scher, S. Ellen Gamble, Julie Barber-Rotenberg, Aykut Üren, **Jeffrey Toretsky**. Novel peptide directed targeting of EWS-FLI1 impairs tumor cell growth. Combined Musculoskeletal Tumor Society/Connective Tissue Oncology Society Meeting, Chicago, IL, October 26-29, 2011 (oral presentation).
73. Gulay Bulut, Sung-Hyeok Hong, Kevin Chen, Elspeth Beauchamp, Said Rahim, George Kosturko, Eric Glasgow, Sivanesan Dakshanamurthy, Hyun-Shik Lee, Ira Daar, **Jeffrey A. Toretsky**, Chand Khanna, Aykut Üren. Small molecule inhibitors of ezrin inhibit the metastasis of Osteosarcoma cells. Combined Musculoskeletal Tumor Society/Connective Tissue Oncology Society Meeting, Chicago, IL, October 26-29, 2011.
74. Jason U. Tilan, Congyi Lu, Joshua Patrick Earnest, Lindsay M. Everhart, Asim Shabir, Alison O'Neill, Shuo Wang, Magdalena Czarnecka, **Jeffrey A. Toretsky**, Joanna Kitlinska. Differential functions of neuropeptide Y in Ewing's sarcoma - hypoxia as a switch. American Association of Cancer Research, Chicago. IL, April 3, 2012.
75. Jared T. Murdoch, Sung-Hyeok Hong, Gulay Bulut, George W. Kosturko, Lauren E. Drebing, **Jeffrey A. Toretsky**, Aykut Uren. Small molecule inhibitor of ezrin inhibits metastasis in a transgenic mouse model of osteosarcoma. American Association of Cancer Research, Chicago. IL, April 3, 2012.
76. George W. Kosturko, Gulay Bulut, Sung-Hyeok Hong, Veronica Rodriguez, Milton Brown, **Jeffrey Toretsky**, Chand Khanna, Mikell Paige, Aykut Uren. Design, synthesis and biological evaluation of 2nd generation ezrin inhibitors for metastatic osteosarcoma. American Association of Cancer Research, Chicago. IL, April 3, 2012.
77. David Solomon, Taeyon Kim, Laura Diaz-Martinez, Joshlean Fair, Abdel Elkahloun, Brent Harris, **Jeffrey Toretsky**, Steven Rosenberg, Neerav Shukla, Marc Ladanyi, Yardena Samuels, C. David James, Hongtao Yu, Jung-Sik Kim, Todd Waldman. Mutational inactivation of STAG2 causes aneuploidy in human cancer. American Association of Cancer Research, Chicago. IL, April 3, 2012.
78. S. Peter Hong, S. Ellen Gamble, Sung-Hyeok Hong, Christina L. Kobs, Karen E. Elsass, Natalie L. South, Philip J. Monroe, Aykut Üren, **Jeffrey A. Toretsky**. LB-316 - Pharmacokinetic modeling optimizes direct inhibition of the 'undruggable' target EWS-FLI1 of Ewing Sarcoma. American Association of Cancer Research, Chicago. IL, April 3, 2012.
79. Julie S. Barber-Rotenberg, Saravana P. Selvanathan, Hayriye V. Erkizan, Maksymilian Chruszcz, Milton L. Brown, Aykut Üren, **Jeffrey A. Toretsky**. EWS-FLI1 as a Molecular Target: Inhibitors for a Disordered Protein. Gordon Research Conference: Intrinsically Disordered Proteins, Mt. Snow, VT, July 2012.
80. Shah, N., Graham G., Li X., Wang J., Khan J., **Toretsky J.A.** HOX gene and associated long noncoding RNA expression correlates with neuroblastoma cell line phenotype and response to 13-cis retinoic acid. Advances in Neuroblastoma Research 2012, Toronto, Ontario. June 2012
81. Shah, N., Graham G., Li X., Wang J., Khan J., **Toretsky J.A.** PBX1 is a Putative Favorable Prognostic Biomarker as a Modulator of Retinoid Response in Neuroblastoma. ASPHO 26th Annual Meeting, Miami, FL. May 2013
82. Shah, N., Graham G., Li X., Wang J., Khan J., **Toretsky J.A.** PBX1 is a Putative Favorable Prognostic Biomarker as a Modulator of Retinoid Response in Neuroblastoma.

- COG Fall Meeting, Young Investigator Symposium, Dallas, TX. November 2013
83. Shah, N., Selich-Anderson, JA, Graham G., Siddiqui H., Li X., Wang J., Khan J., **Toretsky JA**. PBX1 is a Strong Favorable Prognostic Biomarker in Low-Risk and High-Risk Neuroblastoma and is Critical to Retinoid-Mediated Differentiation. Advances in Neuroblastoma Research 2014, Cologne, Germany. May 2014
 84. S. Ellen Gamble, Sung-Hyeok Hong, S. Peter Hong, Steve Summer, Philip J. Monroe, Aykut Üren, **Jeffrey A. Toretsky**. Small molecule YK-4-279 inhibits the ‘undruggable’ target EWS-FLI1 leading to xenograft tumor regression. America Society of Clinical Oncology, Chicago, Ill. June 2013.
 85. AACR 2013
 86. ABRCMS 2013
 87. CTOS 2013
 88. AACR 2014
 89. **Jeffrey Toretsky**, Saravana P. Selvanathan, Garrett T. Graham, Hayriye V. Erkizan, Uta Dirksen, Thanemozhi G. Natarajan, Cathy H. Wu, Elizabeth R. Lawlor, Aykut Üren. EWS-FLI1 is an oncogene in a network and functioning in alternative splicing. Gordon Research Conference Post-transcriptional Regulation. Newport, RI, 2014.
 90. AACR 2015 - Haydar, Yasemine, Tsion, Stefan
 91. Stefan K. Zöllner, Ryan Commins, Sung H. Hong, Hayriye V. Erkizan, **Jeffrey A. Toretsky**. EWS-FLI1 targeted small molecule YK-4-279 synergizes with vinca alkaloids through double hit to mitotic machinery. AACR, Philadelphia, PA. April 2015.
 92. Elaine Yee Lin Chung, Valdemar Priebe, Eugenio Gaudio, Ivo Kwee, Chiara Tarantelli, Andrea Rinaldi, Laura Carrassa, Monica Testoni, Luciano Cascione, Massimo Broggin, **Jeffrey A. Toretsky**, Emanuele Zucca, Francesco Bertoni. The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models. AACR, Philadelphia, PA, April 2015.
 93. RNA 2015 -JT